Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allylestrenol versus progesterone for prevention of late miscarriage and preterm birth
ChiCTR2100053693Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of allylestrenol and progesterone in preterm birth and Pregnancy loss (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Delivery rate before 37 weeks. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
allylestrenolprogesterone
03
Conditions
preterm birthPregnancy loss
Beyond the preview
Go deeper on ChiCTR2100053693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053693.